Asthma Therapeutics
1. Alvesco patent expiration
Treatment: Method of treating inflammatory conditions; Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 year...
ALVESCO's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5775321 | COVIS | Seal configuration for aerosol canister |
Jul, 2015
(10 years ago) | |
| US5683677 | COVIS | Medicinal aerosol formulations |
Nov, 2014
(11 years ago) | |
| US5605674 | COVIS | Medicinal aerosol formulations |
Feb, 2014
(11 years ago) | |
| US6036942 | COVIS | Seal configuration for aerosol canister |
Apr, 2013
(12 years ago) | |
| US5482934 | COVIS | Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions |
Oct, 2017
(8 years ago) | |
| US6264923 | COVIS | Medicinal aerosol formulation of ciclesonide and related compounds |
May, 2018
(7 years ago) | |
| US6006745 | COVIS | Device for delivering an aerosol |
Dec, 2016
(9 years ago) | |
| US6120752 | COVIS | Medicinal aerosol products containing formulations of ciclesonide and related steroids |
May, 2018
(7 years ago) | |
| US8371292 | COVIS | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 20, 2011 |
| M(M-125) | Dec 17, 2015 |
Drugs and Companies using CICLESONIDE ingredient
NCE-1 date: 20 October, 2010
Market Authorisation Date: 10 January, 2008
Dosage: AEROSOL, METERED
More Information on Dosage
ALVESCO family patents
2. Omnaris patent expiration
Treatment: Nasal treatment of seasonal and perennial allergic rhinitis symptoms; Treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. treatment ...
OMNARIS's oppositions filed in EPO
OMNARIS IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5482934 | COVIS | Pregna-1,4-diene3,20-dione-16-17-acetal-21 esters, process for their preparation, composition, and methods for the treatment of inflammatory conditions |
Oct, 2017
(8 years ago) | |
| US7235247 | COVIS | Pharmaceutical composition for application to mucosa |
Apr, 2019
(6 years ago) | |
| US6767901 | COVIS | Ciclesonide contained pharmaceutical composition for application to mucosa |
Oct, 2020
(5 years ago) | |
| US6939559 | COVIS | Pharmaceutical composition for application to mucosa |
Apr, 2019
(6 years ago) | |
| US8383611 | COVIS | Ciclesonide containing aqueous pharmaceutical composition |
Oct, 2020
(5 years ago) | |
| US8371292 | COVIS | Use of ciclesonide for the treatment of respiratory diseases |
Feb, 2028
(2 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 20, 2011 |
Drugs and Companies using CICLESONIDE ingredient
NCE-1 date: 20 October, 2010
Market Authorisation Date: 20 October, 2006
Dosage: SPRAY, METERED
How can I launch a generic of OMNARIS before it's drug patent expiration?
More Information on Dosage
OMNARIS family patents